Acquisition Closed October 16, 2026
BioLife Solutions, Inc. acquisition by Repligen Corporation (closed): stock options and RSUs
Completed: SEC filings show this deal closed by October 16, 2026. Repligen acquired BioLife Solutions for 0.1442 Repligen share plus $11.25 in cash per share.
- Buyer
- Repligen Corporation
- What holders receive
- 0.1442 Repligen share plus $11.25 in cash per share
- Agreement signed
- July 21, 2026
- Shareholder vote
- October 5, 2026
- Expected closing
- In the fourth quarter of 2026
- Closed
- October 16, 2026
How equity awards are treated
The filing's equity award section could not be summarized reliably. Read the source filing below.
What this means for your taxes
- Shares you own outright get cash, stock or both. Even in a deal that is otherwise tax-free, the cash part is generally taxable to the extent of your gain.
- ESPP shares sold in the deal within 2 years of the offering date or 1 year of purchase are a disqualifying disposition: part of the gain is taxed as ordinary income.
- Timing: expected closing is in the fourth quarter of 2026. If it could fall either side of December 31, the payout lands in a different tax year, which can matter for estimated payments and for bunching deductions.
General rules, not advice for your situation. Your award agreement and the merger agreement control. Full guide: stock options and RSUs in an acquisition →
Source
From the company's SEC filing: DEFM14A (accession 0001193125-26-383837). Last checked against the filing on November 19, 2026. Found an error? Corrections are made the same day; see how we check.
Questions
What will BioLife Solutions, Inc. shareholders receive?
Under the merger agreement, holders receive 0.1442 Repligen share plus $11.25 in cash per share.
What happens to BioLife Solutions, Inc. stock options and RSUs?
See the treatment of equity awards section in the source filing.
When will the deal close?
The filing expects closing in the fourth quarter of 2026. SEC filings show it closed by October 16, 2026.